CONTENTS

 Issue 82 | May 2019

In association with

a tranquil mind

A form of ketamine for use as a treatment for depression is exciting interest 

EMA: the journey

The EMA is lowering the flag of its London base and moving to the Netherlands

CBD in the uk

Exploring the potential of the medical cannabis market in the UK

open science

Putting aside profits and patent protection in favour of greater collaboration

memory loss

Meet the innovative treatments helping researchers to fight memory loss

Shared spaces

RUNLABS: providing flexible lab space to help new biotech firms find their feet

02/23/2024 21:24:20
  • Home | Where is my mind?
  • In this issue
  • Scandinavian Health Company Insight
  • Scandinavian Health
  • Contents
  • NSF
  • News
  • Daiichi Jitsugyo
  • The pharma industry briefing
  • International Cannabis and Cannabinoid Institute (ICCI) Company Insight
  • International Cannabis and Cannabinoid Institute (ICCI)
  • Thumbs up for esketamine sheds light on potential for ketamine
  • Phoenix group Company Insight
  • Phoenix group
  • Charting the life and times of the EMA as it leaves London
  • Swiss WorldCargo
  • Capsugel Company Insight
  • Capsugel
  • Medical cannabis in the UK: how has the roll out gone so far?
  • EmboCaps
  • Barc Lab
  • Drug development: the researchers driving an open-science approach
  • Freudenberg Medical
  • Albypharma
  • The drugs fighting memory loss
  • Senn Chemicals
  • Pharma Hemp
  • RUNLABS: empowering life science through flexible working environments
  • Spirax Sarco
  • Spirax Sarco Company Insight
  • Events
  • Accurate Biometrics Company Insight
  • Accurate Biometrics
  • B&W Tek
  • Next issue
  • Pfanstiehl
  • Centaur Clinical | Company Insight
  • Centaur Clinical
  • Hapa Company Insight
  • Contract Pharmaceuticals Limited Canada
04/25/2019 00:00:00